Comment on

• Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.

  Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Clinical Trial.
• TRIBE2 results and toxicity.

  Zhang J, Cai Y, Xie X, Hu H, Deng Y. Zhang J, et al. Lancet Oncol. 2020 Jun;21(6):e298. doi: 10.1016/S1470-2045(20)30270-9. Lancet Oncol. 2020. PMID: 32502450 No abstract available.
• TRIBE2 results and toxicity.

  Avallone A, Giuliani F. Avallone A, et al. Lancet Oncol. 2020 Jun;21(6):e299. doi: 10.1016/S1470-2045(20)30273-4. Lancet Oncol. 2020. PMID: 32502451 No abstract available.